Quest Diagnostics Inc
NYSE:DGX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
123.78
163.89
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Quest Diagnostics Inc
Quest Diagnostics Inc
Cash & Cash Equivalents
Quest Diagnostics Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash & Cash Equivalents
$764m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
DaVita Inc
NYSE:DVA
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Chemed Corp
NYSE:CHE
|
Cash & Cash Equivalents
$238.5m
|
CAGR 3-Years
102%
|
CAGR 5-Years
92%
|
CAGR 10-Years
29%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash & Cash Equivalents
$6.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
20%
|
|
|
Cigna Corp
NYSE:CI
|
Cash & Cash Equivalents
$5.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash & Cash Equivalents
$1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
33%
|
CAGR 10-Years
10%
|
|
Quest Diagnostics Inc
Glance View
Quest Diagnostics Inc. is a leading provider of diagnostic testing and information services, playing a crucial role in the healthcare ecosystem. With a legacy dating back to the 1960s, Quest has established itself as a trusted partner for healthcare providers by offering a wide range of testing services, including routine blood tests, genetic testing, and specialized diagnostics for chronic diseases. The company's innovative approach to testing, bolstered by its extensive network of laboratories and state-of-the-art technology, ensures accurate and timely results, empowering patients and physicians alike to make informed healthcare decisions. As an industry leader, Quest not only aids in clinical decision-making but also plays a pivotal role in the ongoing shift toward value-based care, which emphasizes quality over quantity in patient treatment. For investors, Quest Diagnostics represents an attractive opportunity due to its strong financial performance and growth potential. The company benefits from a robust demand for diagnostic testing services, especially in the wake of the COVID-19 pandemic, which has heightened awareness of the importance of timely medical diagnostics. Quest's investment in cutting-edge technology and telehealth solutions positions it well to adapt to the evolving healthcare landscape. With a track record of consistent revenue growth and a commitment to returning value to shareholders through dividends and share buybacks, Quest Diagnostics stands out as a solid investment in the healthcare sector, blending stability with innovation in a critical industry.
See Also
What is Quest Diagnostics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
764m
USD
Based on the financial report for Sep 30, 2024, Quest Diagnostics Inc's Cash & Cash Equivalents amounts to 764m USD.
What is Quest Diagnostics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
16%
Over the last year, the Cash & Cash Equivalents growth was 434%. The average annual Cash & Cash Equivalents growth rates for Quest Diagnostics Inc have been -8% over the past three years , 12% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
